Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
PrECOG, LLC.
University of Chicago
Mayo Clinic
Peking University First Hospital
Jiangsu Cancer Institute & Hospital
Medical College of Wisconsin
Institut Bergonié
Novartis
University of Kansas Medical Center
M.D. Anderson Cancer Center
Assiut University
Institut Bergonié
Helwan University
Peking Union Medical College Hospital
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Ruijin Hospital
Region Skane
Fundación Sociedad Española de Oncologia Médica
West China Hospital
Zhejiang Cancer Hospital
Fujian Medical University
Shanghai Chest Hospital
Azienda Ospedaliero-Universitaria di Modena
Turku University Hospital
University of Roma La Sapienza
RenJi Hospital